Precursor Condition
Squamous Cell Intraepithelial Neoplasia
CI-CAN-00001551SIL · SINExplore in graph →
Precursor19 active trials
- NCIt
- C8334
Loading cancer entity…
Loading cancer entity…
Precursor Condition
CI-CAN-00001551SIL · SINExplore in graph →
Clinical trials
115 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06233331 | Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV | not yet recruiting | Phase 1 | 9 | Emory UniversityOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT02698293 | PDT Plus Vitamin D3 for Anal Dysplasia | withdrawn | Phase 1 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT03913117 |
| Study of Treatment for HPV16+ ASC-US or LSIL(PVX-6) |
| recruiting |
| Phase 1 |
| 30 |
| University of Alabama at BirminghamOTHER |
| 1 |
| May 15, 2026 |
| clinicaltrials |
| NCT05334004 | Lopinavir/Ritonavir in PLWH With High-Grade AIN | recruiting | Phase 1 | 21 | University of Wisconsin, MadisonOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT05717621 | Clinical Trial With Local Decitabine Treatment of HPV-Induced VIN Grade 2/3 (DelVIN)(DelVIN) | completed | Phase 1 | 29 | ViMREX GmbHINDUSTRY | 1 | Feb 11, 2025 | clinicaltrials |
| NCT03792516 | Artesunate Ointment for the Treatment of High Grade Vulvar Intraepithelial Neoplasia (HSIL VIN2/3)(ART-VIN) | completed | Phase 1 | 15 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT03100045 | Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)(ART-AIN) | completed | Phase 1 | 18 | Johns Hopkins UniversityOTHER | 1 | Nov 3, 2021 | clinicaltrials |
| NCT03697226 | Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection. | completed | Phase 1 | 8 | Antiva BiosciencesINDUSTRY | 1 | Jan 13, 2021 | clinicaltrials |
| NCT03676101 | Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | completed | Phase 1 | 90 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT03677960 | Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection | terminated | Phase 1 | 6 | Antiva BiosciencesINDUSTRY | 2 | Jul 24, 2019 | clinicaltrials |
| NCT03239223 | Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection | completed | Phase 1 | 16 | Antiva BiosciencesINDUSTRY | 2 | Jul 10, 2019 | clinicaltrials |
| NCT03202992 | Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection | completed | Phase 1 | 57 | Antiva BiosciencesINDUSTRY | 2 | Feb 7, 2019 | clinicaltrials |
| NCT01923116 | Therapeutic HPV-16 Vaccination for the Treatment of Anal Dysplasia(VACCAIN-T) | completed | Phase 1 / Phase 2 | 40 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Mar 15, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Aug 18, 2026source: clinicaltrials